Lymphoma

>

Latest News

Liso-cel Potentially More Effective in Earlier Lines of Treatment for MCL
Liso-cel Potentially More Effective in Earlier Lines of Treatment for MCL

June 15th 2024

A subgroup analysis of the TRANSCEND NHL 001 trial demonstrated that liso-cel may be more effective in earlier lines of treatment for patients with mantle cell lymphoma.

Adding Tucidinostat to R-CHOP Demonstrates Safety, Efficacy in DLBCL Subtype
Adding Tucidinostat to R-CHOP Demonstrates Safety, Efficacy in DLBCL Subtype

June 6th 2024

Brentuximab Vedotin Regimen Improves PFS, QoL Over Chemo in Classical Hodgkin Lymphoma
Brentuximab Vedotin Regimen Improves PFS, QoL Over Chemo in Classical Hodgkin Lymphoma

June 1st 2024

FDA Approves Liso-Cel for Relapsed/Refractory Mantle Cell Lymphoma
FDA Approves Liso-Cel for Relapsed/Refractory Mantle Cell Lymphoma

May 30th 2024

Venetoclax May Provide Cost Savings to Patients vs BTK Inhibitors for CLL/SLL
Venetoclax May Provide Cost Savings to Patients vs BTK Inhibitors for CLL/SLL

May 17th 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.